Clinicopathologic features of the nine patients with primary diffuse large B cell lymphoma of the breast.
ABSTRACT Non-Hodgkin lymphomas of the breast are uncommon cancers that occur as either primary extranodal diseases or secondary localizations of a systemic disease. The term "primary breast lymphoma" (PBL) is used to define malignant lymphomas primarily occurring in the breast in the absence of previously detected lymphoma localizations. In this report, we analyzed nine patients with primary diffuse large B cell lymphoma (DLBCL) of breast.
Patients with newly diagnosed PBLs treated between 1997 and 2009 in five institutions were retrospectively evaluated.
The median age of the patients with PBL was 49 years (range 30-82 years), and four patients had left-sided and five had right-sided disease. All of the nine patients were classified as DLBCL. Five patients with DLBCL received chemotherapy followed by involved-field or elective-field radiotherapy and four received chemotherapy alone. Complete remission (CR) following primary treatment for all patients with PBL except for two cases was obtained. In two patients, recurrence occurred. At the median follow-up of 24.2 months, the 5-year OS rate was 76.2%. Univariate analysis indicated that age, ECOG PS, clinical stage, international prognostic index score, lactate dehydrogenase levels and the presence of B symptoms were not important prognostic factors in our study.
Our series contained a small sample size, but it is interesting because it included only DLBCL cases. However, definitive conclusions about treatment and follow-up options of patients cannot be made in such a small series of patients. There are very few reports of patients with PBL treated with R-CHOP rather than CHOP alone. The followup is probably still too short and sample size very few to know how R-CHOP compares with CHOP-treated patients in other series, but this is definitely worth looking at in more detail when reasonable median follow-up has been achieved and sample size are sufficient.
[Show abstract] [Hide abstract]
ABSTRACT: Primary breast lymphoma is a rare form of non-Hodgkin lymphoma with some distinct clinical features. The most common histopathological type is diffuse large B-cell lymphoma (DLBCL), but other less frequent subtypes are also encountered. In this review, we describe the characteristics of primary breast DLBCL, with emphasis on pathogenesis, staging, risk stratification and prognosis. In addition, key issues regarding therapy and various available therapeutic modalities are addressed, as well as the role of rituximab in therapy and whether central nervous system prophylaxis is still routinely required. There are very few prospective clinical studies addressing therapy, and available data rely mostly on retrospective case series involving small numbers of patients. Our conclusions and proposed recommendations are therefore not offered as formal guidelines. This review attempts to represent an unbiased analysis of the published data and is intended as a useful aid for clinicians treating this uncommon type of extra nodal lymphoma.Annals of Oncology 05/2013; 24(9). DOI:10.1093/annonc/mdt192 · 6.58 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: After publication of this work (Mouna et al, 2012), we noted that we had inadvertently included Bodmer Alexandre, Castiglione-Gertsch Monica and Pierre Yves Dietrich as authors of the study. The list of authors has now been corrected and the Authors' contributions and Competing interests section modified accordingly.World Journal of Surgical Oncology 10/2012; 10(1):217. DOI:10.1186/1477-7819-10-217 · 1.20 Impact Factor
Article: Primary breast lymphomaThe Kaohsiung journal of medical sciences 08/2013; 29(8):464-5. DOI:10.1016/j.kjms.2012.12.008 · 0.81 Impact Factor